Nitric oxide (no) pathway and locomotor hyperactivity towards dopaminomimetics in rats

Polish Journal of Pharmacology

Volumn 49, Issue 5, 1997, Pages 291-298

  Przegalinski, Edmund ^a   Filip, Małgorzata ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

DA indirect and direct agonists; Locomotor activity; NO pathway; Rats

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 7 NITROINDAZOLE; AMPHETAMINE; BROMOCRIPTINE; COCAINE; DOPAMINE RECEPTOR STIMULATING AGENT; MOLSIDOMINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; RECEPTOR SUBTYPE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HYPERACTIVITY; LOCOMOTION; MALE; NONHUMAN; RAT;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; AMPHETAMINE; ANIMALS; BROMOCRIPTINE; COCAINE; DOPAMINE AGONISTS; ENZYME INHIBITORS; HYPERKINESIS; INDAZOLES; MALE; MOLSIDOMINE; MOTOR ACTIVITY; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RATS; RATS, WISTAR;

EID: 0030727851     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Abekawa T., Ohmori T., Koyama T.: Effect of NO synthase inhibition on behavioral changes induced by single administration of methamphetamine. Brain Res., 1994, 666, 147-150.
2. Abekawa T., Ohmori T., Koyama T.: Effects of repeated administraton of a high dose of methamphetamine on dopamine and glutamate release in rat striatum and nucleus accumbens. Brain Res., 1994, 643, 276-281.
3. Alheid G. F., Heimer L.: New perspectives in basal forebrain organization of special relevance for neuropsychiatric disorders: the striatopallidal, amygdaloid and corticopetal components of substantia innominata. Neuroscience, 1988, 27, 1-39.
4. Bowyer J. F., Clausing P., Gough B., Slikker W. Jr., Holson R. R.: Nitric oxide regulation of methamphetamine-induced dopamine release in caudate/putamen. Brain Res., 1995, 699, 62-70.
5. Bredt D. S., Snyder S. H.: Nitric oxide, a novel neuronal messenger. Neuron, 1992, 8, 3-11.
6. G-nitro-L-arginine methyl ester and other esters of arginine are muscarinic receptor antagonists. Circ. Res., 1993, 72, 387-395.
7. Deutch A. Y., Cameron D. S.: Pharmacological characterization of dopamine systems in the nucleus accumbens core and shell. Neuroscience, 1992, 46, 49-56.
8. Di Chiara G., Imperato A.: Drugs of abuse preferentially stimulate DA release in the mesolimbic system of freely moving rats. Proc. Nat. Acad. Sci. USA, 1988, 85, 5274-5278.
9. Filip M., Przegaliński E.: The role of the nitric oxide (NO) pathway in the discriminative stimulus effects of amphetamine and cocaine in rats. Pharmacol. Biochem. Behav., in press.
10. Garthwaite J.: Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci., 1991, 14, 60-67.
11. Gonzales M. C., Linares J. D., Santos M., Llorente E.: Effects of nitric oxide donors sodium nitroprusside and 3-morpholinosydnonimine on prolactin secretion in conscious rats. Neurosci. Lett., 1996, 203, 167-170.
12. Guevara-Guzman R., Emson P.C., Kendrick K. M.: Modulation of in vivo striatal transmitter release by nitric oxide and cyclic GMP. J. Neurochem., 1994, 62, 807-810.
13. Haberny K. A., Pou S., Ecoles C. U.: Potentiation of quinolinate-induced hippocampal lesions by inhibition of NO synthesis. Neurosci. Lett., 1992, 146, 187-190.
14. Imperato A., Scrocco M. G., Bacchi S., Angelucci L.: NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatus. Eur. J. Pharmacol., 1990, 187, 555-556.
15. ω-nitroarginine on NMDA-evoked striatal dopamine overflow. Brain Res. Bull., 1994, 34, 483-486.
16. Jaber M., Robinson S. W., Missale C., Caron M. G.: Dopamine receptors and brain function. Neuropharmacology, 1996, 35, 1503-1519.
17. Jongen-Rělo A. L., Groenewegen H. J., Voorn P.: Distribution and regulation of dopamine receptors in the nucleus accumbens of the rat. Soc. Neurosci. Abstr. 1992, 18, 99.
18. Jongen-Rělo A. L., Voorn P., Groenewegen H. J.: Immunohistochemical characterization of the shell and core territories of the nucleus accumbens in the rat. Eur. J. Neurosci., 1994, 6, 1255-1264.
19. Kalisch B. E., Connop B. P., Jhamandas K., Beninger R. J., Boegman R. J.: Differential action of 7-nitro indazole on rat brain nitric oxide synthase. Neurosci. Lett., 1996, 219, 75-78.
20. Kalivas P. W., Alesdatter J. E.: Involvement of N-methyl-D-aspartate receptor stimulation in the ventral tegmental area and amygdala in behavioral sensitization to cocaine. J. Pharmacol. Exp. Then, 1993, 267, 486-495.
21. Kapas L., Krueger J.M.: Nitric oxide donors SIN-1 and SNAP promote nonrapid-eye-movement sleep in rats. Brain Res. Bull., 1996, 41, 293-298.
22. Kita Y., Fukuyama S., Hirasawa Y: Close correlation between nitric oxide (NO) formation from NO releasers and the biological activities of these agents in rats. Jpn. J. Pharmacol., 1995, 69, 69-74.
23. Krebs M. O., Desce J. M., Kernel M. L., Gauchy C., Godeheu G., Cheramy A., Glowinski J.: Glutamatergic control of dopamine release in the rats striatum: evidence for presynaptic N-methyl-D-aspartate receptors on dopaminergic nerve terminals. J. Neurochem., 1991, 56, 81-85.
24. Kuczenski R., Segal D. S.: Differential effects of amphetamine and dopamine uptake blockers (cocaine, nomifensine) on caudate and accumbens dialysate dopamine and 3-methoxytyramine. J. Pharmacol. Exp. Ther., 1992, 262, 1085-1094.
25. Lin A. M.-Y, Kao L.-S., Chai C.Y.: Involvement of nitric oxide in dopaminergic transmission in rat striatum: an in vivo electrochemical study. J. Neurochem., 1995, 65, 2043-2049.
26. 3H]dopamine release from striatal slices. J. Neurosci. Res., 1993, 35, 192-198.
27. 3H]gluta- mate by striatal synaptosomes, J. Neurochem., 1994, 63, 2108-2117.
28. MacKenzie G. M., Rose S., Bland-Ward Ph. A., Moore Ph. K., Jenner P., Marsden C. D.: Time course of inhibition of brain nitric oxide synthase by 7-nitroindazole. NeuroReport, 1994, 5, 1993-1996.
29. Maj J., Rogóz Z., Skuza G.: Locomotor hyperactivity induced by MK-801 in rats. Pol. J. Pharmacol. Pharm., 1991, 43, 449-458.
30. Melis M. R., Argiolas A.: Nitric oxide donors induce penile erection and yawning when injected in the central nervous system. Eur. J. Pharmacol., 1995, 294, 1-9.
31. Moncada S., Palmer R. M. J., Higgs E. A.: Biosynthesis of nitric oxide from L-arginine: a pathway for the regulation of cell function and communication. Biochem. Pharmacol., 1989, 38, 1709-1715.
32. Moncada S., Palmer R. M. J., Higgs E. A.: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev., 1991, 43, 109-142.
33. Moore P. K., Wallace P., Gaffen Z., Hart S. L., Babbedge R. C.: Characterization of the novel nitric oxide synthase inhibitor 7-nitro indazole and related indazoles: antinoceptive and cardiovascular effects. Brit. J. Pharmacol., 1993, 110, 219-224.
34. Nathan C.: Nitric oxide as a secretory product of mammalian cells. FASEB, 1992, 6, 3051-3064.
35. Ohno M., Watanabe S.: Nitric oxide synthase inhibitors block behavioral sensitization to methamphetamine in mice. Eur. J. Pharmacol., 1995, 275, 39-44.
36. Pudiak C. M., Bozarth M. A.: L-NAME and MK-801 attenuate sensitization to the locomotor-stimulating effect of cocaine. Life Sci., 1993, 53, 1517-1524.
37. Rees D. D., Palmer R. M. J., Moncada S.: Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc. Nat. Acad. Sci. USA, 1989, 86, 3375-3378.
38. Rees D. D., Palmer R. M. J., Schullz R., Hodson H. R., Moncada S.: Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Brit. J. Pharmacol., 1990, 101, 746-752.
39. Salter M., Duffy C., Hazelwood R.: Determination of brain nitric oxide synthase inhibition in vivo: ex vivo assays of nitric oxide synthase can give incorrect results. Neuropharmacology, 1995, 34, 327-334.
40. Shimizu N., Duan S., Hori T., Oomura Y.: Glutamate modulates dopamine release in the striatum as measured by brain microdialysis. Brain Res. Bull., 1990, 25, 99-102.
41. Suva M. T., Rose S., Hindmarsh J. G., Aislaitner G., Gorrod J. W., Moore P. K., Jenner P., Marsden C. D.: Increased striatal dopamine efflux in vivo following inhibition of cerebral nitric oxide synthase by the novel monosodium salt of 7-nitro indazole. Brit. J. Pharmacol., 1995, 114, 257-258.
42. Starr M. S., Starr B. S,: Do NMDA receptor-mediated changes in motor behaviour involve nitric oxide? Eur. J. Pharmacol., 1995, 272, 211-217.
43. Stewart J., Deschamps S.-E., Amir S.: Inhibition of nitric oxide synthase does not block the development of sensitization to the behavioral activating effects of amphetamine. Brain Res., 1994, 641, 141-144.
44. Strasser A., McCarron R. M., Ishii H., Stanimirovic D., Spatz M.: L-arginine induces dopamine release from the striatum in vivo, NeuroReport, 1994, 5, 2298-2300.
45. Tanayama S., Fujita T., Shirakawa Y., Suzuoki Z.: Metabolic fate of 5-ethoxy-carbonyl-3-morpholino-sydnonimine (SIN-10). 1. Absorption, excretion and tissue distribution in rats and mice. Jpn. J. Pharmacol., 1970, 20, 413-423.
46. Vanhoutte P. M.: Molsidomine is a donor of EDRF. J. Cardiovasc. Pharmacol., 1989, 14, S139-140.
47. Vaupel D. B., Kimes A. S., London E. D.: Comparison of 7-nitroindazole with other nitric oxide synthase inhibitors as attenuators of opioid withdrawal. Psychopharmacology, 1995, 118, 361-368.
48. Vincent S. R., Kimura H.: Histochemical mapping of nitric oxide synthase in rat brain. Neuroscience, 1992, 46, 755-784.
49. Wolf M. E., Khansa M. R.: Repeated administration of MK-801 produces sensitization to its own locomotor stimulant effects but blocks sensitization to amphetamine. Brain Res., 1991, 562, 164-168.
50. Zahm D. S., Brog J. S.: On the significance of subterritories in the "accumbens" part of the rat ventral striatum. Neuroscience, 1992, 50, 751-767.
51. Zhu X.-Z., Luo L.-G.: Effect of nitroprusside (nitric oxide) on endogenous dopamine release from rat striatal slices. J. Neurochem., 1992, 59, 932-935.